Macular Degeneration and Term Life Insurance in 2026

Macular degeneration affects your life insurance rates because underwriters evaluate the progression risk and associated health complications. Vision loss itself is not the primary concern. The cardiovascular factors that often accompany age-related macular degeneration (AMD) and the functional limitations matter more. But here’s what many people do not realize: two applicants with the exact same diagnosis can receive dramatically different rates depending on which carrier evaluates them.

Why Macular Degeneration Affects Your Rates

Underwriters view macular degeneration through two lenses. First, the condition itself signals underlying vascular health issues. AMD shares common risk factors with heart disease and stroke. Second, the disease progression pattern helps predict future complications.

When we help clients in this situation, carriers typically focus on whether you have dry AMD (slower progression) or wet AMD (faster, more aggressive). Dry macular degeneration accounts for about 90% of cases and progresses gradually over years. Wet macular degeneration represents higher risk because abnormal blood vessel growth can cause rapid vision loss.

Your current visual acuity measurements matter significantly. Someone maintaining 20/40 vision with early dry AMD presents very differently than someone with 20/200 vision and active wet AMD requiring anti-VEGF injections.

What Underwriters Actually Evaluate

The underwriting checklist for macular degeneration includes specific factors that move your classification up or down the rating table.

Disease type and stage top the list. Early dry AMD with minimal drusen (yellow deposits) receives the most favorable consideration. Intermediate dry AMD with larger drusen increases the rating. Wet AMD automatically places you in a higher risk category regardless of treatment response.

Current treatment tells underwriters about disease severity. If you receive regular anti-VEGF injections (Lucentis, Eylea, Avastin), carriers know you have active wet AMD. The frequency of injections and treatment response become critical data points.

Vision function in both eyes matters more than you might expect. If one eye has advanced disease but the other maintains good vision, that works in your favor. Bilateral advanced disease with significant vision loss in both eyes results in higher ratings.

Recent ophthalmology reports within the past six months carry substantial weight. Underwriters want to see stable disease rather than active progression. Documentation showing no new hemorrhages, stable fluid levels on OCT scans, and maintained vision between visits all help your case.

Comorbid conditions affect the final decision. Many applicants with AMD also have hypertension, high cholesterol, or diabetes. Each additional condition compounds the rating.

How Table Ratings Work for Your Situation

Life insurance companies use table ratings to price higher-risk applicants. Standard rates represent the baseline for healthy individuals. Table ratings add percentage increases above that baseline.

Table 1 adds 25% to standard rates. Table 2 adds 50%. Table 4 doubles the premium. Table 6 triples it. Each table represents an additional 25% increment.

Here’s what this means in actual dollars. A 55-year-old looking at a $500,000 20-year term policy might pay $115 per month at standard rates. Table 2 brings that to roughly $172 per month. Table 4 pushes it to $230 monthly. That’s the difference between $2,760 and $4,140 annually.

Early dry AMD with good vision typically lands in the Table 1 to Table 2 range. Intermediate dry AMD with some vision impact usually falls between Table 2 and Table 4. Wet AMD under treatment commonly receives Table 4 to Table 6 ratings. Advanced wet AMD with significant bilateral vision loss may require Table 8 or higher.

The age factor compounds these numbers. A 40-year-old with early dry AMD faces minimal impact because the condition rarely causes severe complications at that age. A 65-year-old with the same diagnosis faces steeper ratings because the progression timeline and mortality risk increase.

Macular Degeneration Rates Across Different Carriers

Different carriers rate macular degeneration with surprising variation. One company’s Table 4 becomes another company’s Table 2 for the identical health profile. This happens because each carrier uses proprietary underwriting guidelines based on their claims experience and risk models.

We have seen cases where the rating spread reached four tables between the best and worst offers. That translates to thousands of dollars over a 20-year term. Shopping multiple carriers is not optional if you want the best rate. It’s the only way to find which company’s underwriting philosophy aligns most favorably with your specific situation.

This is where working with an independent agency makes the biggest financial difference. A captive agent representing one carrier gives you one quote at whatever that company decides. We compare your application across many different carriers simultaneously, then present the best options.

Insurance By Heroes was founded by a former first responder and military spouse. Every member of our team has a background in public service. That service-first mentality means we apply the same level of care and thoroughness to every client, regardless of background. We treat finding your best rate as our mission, not just a transaction.

Whole Life Insurance and Universal Life Insurance with Macular Degeneration

Term life insurance represents the most affordable option for most people with macular degeneration, but whole life and universal life policies offer permanent coverage with different underwriting considerations.

Whole life insurance costs significantly more but builds cash value and provides lifetime coverage. The underwriting remains just as strict. You face the same table ratings based on disease type and progression. However, the permanent nature means carriers evaluate long-term risk more conservatively. Expect whole life premiums to reflect a rating one to two tables higher than comparable term coverage.

Universal life insurance provides flexible premiums and death benefits with permanent coverage. Underwriting evaluates macular degeneration identically to term and whole life policies. The advantage comes in premium flexibility. During years when your budget tightens, you can reduce payments (though this affects the death benefit and cash value accumulation).

Guaranteed universal life (GUL) policies offer a middle ground. They provide permanent coverage at lower premiums than traditional whole life by minimizing cash value accumulation. For someone with macular degeneration concerned about outliving term coverage, GUL often provides the most cost-effective permanent solution.

Best Companies for Life Insurance with Macular Degeneration

While we cannot name specific carriers, understanding which company characteristics favor macular degeneration applicants helps focus the search.

Look for carriers with separate underwriting classifications for dry versus wet AMD. Companies that lump all macular degeneration into one category typically offer less competitive rates. Carriers with nuanced guidelines recognizing early, intermediate, and advanced stages provide better pricing for controlled cases.

Some companies specialize in age 50-plus applicants. These carriers build their risk models around conditions like AMD that predominantly affect older individuals. Their underwriting guidelines often prove more favorable than companies focused primarily on younger, healthier applicants.

Carriers offering accelerated underwriting programs rarely accept macular degeneration cases through those fast-track processes. You will need traditional underwriting with medical records review. Companies with efficient medical records departments and experienced underwriters process these applications faster and more accurately.

The best company for your neighbor with wet AMD receiving monthly injections may not be the best for you with early dry AMD and 20/30 vision. This is precisely why shopping your case across multiple carriers matters so much.

Positioning for the Best Outcome

Several actions directly improve your rating before applying.

Get a comprehensive ophthalmology exam within 30 days of application. Fresh documentation showing current disease status eliminates underwriter uncertainty. The report should include visual acuity measurements for both eyes, OCT imaging results, and a clear statement about disease stability or progression.

If you take AREDS2 vitamins (the vitamin formulation proven to slow AMD progression), document this. It demonstrates you are actively managing the condition. While it will not drop you a full table, it contributes to the overall profile of a compliant, proactive patient.

Control any related conditions before applying. Get your blood pressure optimized. Manage cholesterol levels. If you smoke, quit at least 12 months before applying (smoking accelerates AMD and destroys life insurance rates independently).

Gather at least two years of ophthalmology records. Underwriters want to see the progression pattern. Stable disease over 24 months significantly strengthens your application compared to a single snapshot.

Time your application strategically. Do not apply immediately after a diagnosis or during active treatment changes. Wait until you have established stability on your current regimen. For wet AMD, this means stable injection frequency and no new hemorrhages for at least six months.

Common Mistakes That Cost Money

Applying through one carrier and accepting whatever rate they offer is the most expensive mistake. You have no idea if that Table 4 rating represents the best available or if another carrier would have offered Table 2. The premium difference over 20 years could exceed $15,000.

Failing to disclose treatment history backfires during the medical records review. Some applicants think omitting anti-VEGF injections will help their case. When underwriters discover undisclosed treatment, they assume the worst-case scenario and rate accordingly, or decline coverage entirely.

Waiting to apply because you think rates will improve rarely works out. Macular degeneration is progressive. Your vision today represents your best-case scenario for insurance purposes. Waiting 12 months means you are one year older (higher base rates) with 12 more months of potential disease progression. The combination pushes you into worse rating territory.

Applying for too little coverage to save money defeats the purpose. If you need $500,000 to protect your family but only buy $250,000 because of the premium, you have simply underfunded the need. Better to get the right amount at Table 4 than half the amount at Table 2.

Not working with someone who understands macular degeneration underwriting costs you money. Many agents have never placed a policy for someone with AMD. They do not know which carriers offer the best classifications or how to position the application for optimal review.

FAQ

How much more does life insurance cost with macular degeneration?

Expect to pay 25% to 100% above standard rates depending on disease type and severity. Early dry AMD typically adds 25% to 50%, while wet AMD under treatment often doubles premiums. A policy costing $100 monthly at standard rates would run $125 to $200 monthly with macular degeneration.

Can I get approved for life insurance with macular degeneration?

Yes, most people with macular degeneration get approved for coverage. Declines are rare and typically involve only the most advanced cases with severe bilateral vision loss and multiple complications. Table-rated approval is the normal outcome.

Should I wait to apply until my condition improves?

No, because macular degeneration is progressive and you age while waiting. Both factors increase your premium. Apply when your condition is stable, not when it is at its best, because that moment may never come.

What documentation do I need for the application?

You need recent ophthalmology records (within six months) including visual acuity measurements, OCT imaging results, treatment history, and a statement about disease stability. At least two years of follow-up records help underwriters see the progression pattern.